Antitumor effect on the yeast polysaccharide preparation in syngeneic mouse tumor models.

Abstract

Antitumor effect of our Candida utilis glucomannan preparation (YPS) was evaluated in two syngeneic transplantable tumors ; the Lewis lung carcinoma (3LL) in C57BL/6 (B6) mice and the 3-methylcholanthrene (MCA)-induced fibrosarcoma in C3H/He mice. YPS inhibited preferentially the 3LL pulmonary metastases only when optimal dosage was given at an earlier stage ; 7 daily intraperitoneal (i.p.) doses of 100 mg/kg per dose from the next day of tumor inoculation (1 X 10 /mouse, subcutaneously, s.c.) substantially reduced the number of metastatic nodules, yielding the inhibition ratio 54% on day 21. However, the same treatment delayed until day 8 markedly facilitated the metastatic spread (-105%). Postsurgical-adjuvant therapy with YPS (10 daily i.p. doses of 100 mg/kg per dose from the next day of surgery) was effective in improving the survival rate with no evidence of metastatic growth on day 200, even though the amputation of the tumor-bearing legs was performed after the pulmonary metastases had been established (on day 20). In the MCA-fibrosarcoma model, YPS treatment from day 3 (10 daily doses of 100 mg/kg per dose) was effective in prolonging the survival period. The 3LL local tumor was affected only marginally and temporarily, while the MCA-tumor was not at all.Lewis lung carcinoma ; MCAfibrosarcoma ; antimetastatic effect ; antitumor glucomannan ; Candida utilisIn our previous studies (Kumano et al. 1973(Kumano et al. , 1981, the antitumor yeast glucomannan preparation YPS originally found in this laboratory (Oka et al. 1969) was confirmed for its prophylactic effect against the chemically induced tumor production in mice. The present study was carried out to answer the question whether YPS is also capable of inhibiting any syngeneic tumors or not. Evaluation was made in the 3LL in B6 mice and in the MCA-fibrosarcoma in C3H/He mice. As will be described herein, a dose-and timing-dependent

Antitumor effect of the organogermanium compound Ge-132 on the Lewis lung carcinoma (3LL) in C57Bl/6 (B6) mice.

“…For the tests, cell suspension was prepared from the 10-to 12-day-old tumors as described in a previous paper (Kumano et al 1985). Each specified number of viable cells was contained in a 0.2-ml-portion of the final cell suspension.…”

“…The effect on the local tumor and its metastatic spread in the lungs were evaluated as described in the foregoing paper (Kumano et al 1985). In the experiment with a smaller inoculum size (1 x 104 or 103/mouse), latency before tumor appearance was recorded individually.…”

“…injections of Ge-132 at 100 mg/kg. Survival period was compared to those of the surgery-and the untreated control groups (see also the accompanying paper for more detail (Kumano et al 1985).…”

“…Negative effect of the postsurgical-adjuvant therapy The possible beneficial effect of Ge-132 in the postsurgical-adjuvant model was examined in 1 of 4 groups of mice described in the previous paper (Kumano et al 1985). Ge-132 at a daily dose of 100 mg/kg i.p.…”

A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan

“…Nowadays, it mainly serves either as a dietary supplement aiding in weight loss, diabetes, arterial sclerosis, and constipation, or as an emulsifier and thickener in food processing (Chen et al, 2017a; Wu et al, 2018), which corroborates the old theory of “homology of medicine and food.” In fact, many natural polysaccharides that show potent anti-tumor activity (Kim et al, 2011; Xiao et al, 2017; Zhang, 2017; Deng et al, 2018) derive from edible herbs, such as Lentinus , Cordyceps , Ganoderma lucidum , and Hericium , which themselves are also common cuisine ingredients. Recently, glucomannan extracted from Amorphophallus konjac (Chen et al, 2017a), Bletilla striata (Zhan et al, 2014), Lentinus edodes (Fujii et al, 1978), Aloe vera (Sampedro et al, 2004; Im et al, 2005; Liu et al, 2006; Im et al, 2016; Quezada et al, 2017), and Candida utilis (Kumano et al, 1985) were demonstrated to have similar effect. Moreover, according to the studies reviewed in the present research, glucomannan, mainly from these species, not only is an anti-cancer drug by itself but also works as a targeted carrier that is compatible with various bioactive compounds.…”